Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.35 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541557 | 0.83 | OPRL1 (0.47) | OPRL1VRK1ABL1KCNH2 | |
| SCHEMBL3544013 | 0.80 | OPRL1 (0.49) | OPRL1VRK1ABL1KCNH2 | |
| SCHEMBL3548146 | 0.80 | OPRL1 (0.50) | OPRL1VRK1KCNH2 | |
| SCHEMBL3543380 | 0.78 | OPRL1 (0.41) | OPRL1VRK1KCNH2 | |
| SCHEMBL3540280 | 0.77 | OPRL1 (0.42) | OPRL1VRK1ABL1KCNH2 | |
| SCHEMBL3543476 | 0.74 | ALDH1A1 (0.37) | OPRL1KCNH2 | |
| SCHEMBL3549443 | 0.65 | OPRL1 (0.43) | OPRL1 | |
| SCHEMBL29955433 | 0.62 | ALDH1A1 (0.37) | VRK1 | |
| SCHEMBL335669 | 0.62 | ALDH1A1 (0.37) | VRK1 | |
| SCHEMBL3542829 | 0.60 | BRD9 (0.34) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829586-B2 | Aryl-substituted nitrogen-containing heterocyclic compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | MSD K.K. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1935881-A1 | ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | OPRL1, NPSR1, NPBWR1 | OPRL1 1/4885VRK1 2004/4885ABL1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.